Introduction Results

Conclusion
Hypoglycemia is a common side effect of diabetes treatment that leads to reduced well-being and substantial costs. To date the economic burden of hypoglycemia has not been estimated for Austria.
The aim of this study was to assess shortterm health care costs and productivity losses associated with hypoglycemia among patients with type 1 and type 2 diabetes who were either treated with insulin or sulfonylureas in Austria.
Methods
Cost-of-illness study
An incidence-based methodology was used to calculate the direct and indirect costs of hypoglycemia per person and for Austria in 2015.
Data
A literature review was conducted to identify studies reporting on epidemiology, health care resource use and productivity losses associated with hypoglycemia. This was supplemented by market data regarding pharmaceutical use and expert opinion for care pathways.
Model
A bottom-up approach was used, with the costs of different diabetes types [a] (T1DM, T2DM), different hypoglycemic events [b] (NSDHE, NSNHE, SHE) and different treatment schemes [c] (SU, BOT, O, BBT) being calculated and extrapolated to a national level, based on the estimated incidence rates of hypoglycemia.
Direct costs
Treatment for hypoglycemia (glucagon), in-patient and out-patient services, primary and community services
Indirect costs
Productivity losses (absence from work)
a Direct health care costs and productivity costs arising from hypoglycemia in Austria amounted to approximately € 50 million in 2015.
15.6
34.4
The economic burden of hypoglycemia for Austria per year (2015) a Direct costs were predominantly caused by severe hypoglycemic events, whereas the majority of indirect costs resulted from non-severe hypoglycemic events. a Because the proportion of patients in working age is much smaller in T2DM compared to T1DM, T2DM contributes relatively little to the total amount of indirect costs.
a Direct costs are primarily the result of severe hypoglycemic events, whereas the majority of indirect costs are caused by non-severe hypoglycemic events. 
